New CAR-T therapy targets tough MS cases in early safety trial
NCT ID NCT07587125
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This early study tests a new treatment called S103 (BCMA-CAR T cells) in 9 adults with progressive or hard-to-treat multiple sclerosis (MS). The main goal is to see if the treatment is safe and to find the best dose. Researchers will also look for early signs that it might help control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xijing Hospital
RECRUITINGXi'an, Shaanxi, 710032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?